KRYS Company Profile and Key Details
Krystal Biotech, Inc.
KRYS Stock Price Chart
Stock Price Today
Krystal Biotech, Inc. (KRYS) stock surged +1.43%, trading at $161.30 on NASDAQ, up from the previous close of $159.03. The stock opened at $157.77, fluctuating between $157.25 and $162.48 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Company Information
| Employees | 229 |
| Beta | 0.82 |
| Sales or Revenue | $50.70M |
| 5Y Sales Change% | 19.367% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Krystal Biotech, Inc. (NASDAQ: KRYS) stock price is $161.30 in the last trading session. During the trading session, KRYS stock reached the peak price of $162.48 while $157.25 was the lowest point it dropped to. The percentage change in KRYS stock occurred in the recent session was 1.43% while the dollar amount for the price change in KRYS stock was $2.27.
The NASDAQ listed KRYS is part of Biotechnology industry that operates in the broader Healthcare sector. Krystal Biotech, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Gloria Lin
Accounting Mang.
Dr. Andrew C. Orth
Executive Vice President & Chief Commercial Officer
Mr. Josh Suskin
Director of HR & Operations
Ms. Katherine Tuminello
HR & Office Mang.
Mr. David Glynn
Gen. Counsel, Commercial & Compliance
Mr. John Karakkal
Vice President of North American Sales & Marketing
Dr. Andreas C. Orth
Executive Vice President & Chief Commercial Officer
Mr. Krish S. Krishnan M.B.A., M.S.
Founder, Chairman, Pres & Chief Executive Officer
Ms. Suma M. Krishnan
Founder, Chief Operating Officer, Pres of R&D and Director
Mr. John Garcia
Senior Vice President of U.S. Bus. Sales & Operations
Ms. Meg Dodge
Vice President of Investor Relations & Corporation Communications
Ms. Kathryn A. Romano
Executive Vice President & Chief Accounting Officer
Mr. Ram Kamineni
Senior Vice President of CMC & Technical Operations
Mr. Laurent Goux
Senior Vice President & GM of Europe
KRYS's closing price is 50.05% higher than its 52-week low of $107.50 where as its distance from 52-week high of $219.34 is -26.46%.
Number of KRYS employees currently stands at 229.
Official Website of KRYS is: https://www.krystalbio.com
KRYS could be contacted at phone 412 586 5830 and can also be accessed through its website. KRYS operates from 2100 Wharton Street, Pittsburgh, PA 15203, United States.
KRYS stock volume for the day was 176.36K shares. The average number of KRYS shares traded daily for last 3 months was 269.04K.
The market value of KRYS currently stands at $4.64B with its latest stock price at $161.30 and 28.76M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com